A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation

William T. Abraham, Karl Heinz Kuck, Rochelle L. Goldsmith, Jo Ann Lindenfeld, Vivek Y. Reddy, Peter E. Carson, Douglas L. Mann, Benjamin Saville, Helen Parise, Rodrigo Chan, Phi Wiegn, Jeffrey L. Hastings, Andrew J. Kaplan, Frank Edelmann, Lars Luthje, Rami Kahwash, Gery F. Tomassoni, David D. Gutterman, Angela Stagg, Daniel BurkhoffGerd Hasenfuß

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives: The authors sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25% and 45%. Background: CCM therapy for New York Heart Association (NYHA) functional class III and IV heart failure (HF) patients consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. Methods: A total of 160 patients with NYHA functional class III or IV symptoms, QRS duration <130 ms, and ejection fraction ≥25% and ≤45% were randomized to continued medical therapy (control, n = 86) or CCM (treatment, n = 74, unblinded) for 24 weeks. Peak VO2 (primary endpoint), Minnesota Living With Heart Failure questionnaire, NYHA functional class, and 6-min hall walk were measured at baseline and at 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis with 30% borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events with a pre-specified lower bound of 70%. Results: The difference in peak VO2 between groups was 0.84 (95% Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min, satisfying the primary endpoint. Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 0.001), and 6-min hall walk (p = 0.02) were all better in the treatment versus control group. There were 7 device-related events, yielding a lower bound of 80% of patients free of events, satisfying the primary safety endpoint. The composite of cardiovascular death and HF hospitalizations was reduced from 10.8% to 2.9% (p = 0.048). Conclusions: CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations. (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure; NCT01381172)

Original languageEnglish (US)
JournalJACC: Heart Failure
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Randomized Controlled Trials
Heart Failure
Safety
Exercise Tolerance
Hospitalization
Quality of Life
Equipment and Supplies
Therapeutics
Control Groups

Keywords

  • exercise tolerance
  • heart failure
  • peak VO
  • QRS duration
  • quality of life

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Abraham, W. T., Kuck, K. H., Goldsmith, R. L., Lindenfeld, J. A., Reddy, V. Y., Carson, P. E., ... Hasenfuß, G. (Accepted/In press). A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2018.04.010

A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. / Abraham, William T.; Kuck, Karl Heinz; Goldsmith, Rochelle L.; Lindenfeld, Jo Ann; Reddy, Vivek Y.; Carson, Peter E.; Mann, Douglas L.; Saville, Benjamin; Parise, Helen; Chan, Rodrigo; Wiegn, Phi; Hastings, Jeffrey L.; Kaplan, Andrew J.; Edelmann, Frank; Luthje, Lars; Kahwash, Rami; Tomassoni, Gery F.; Gutterman, David D.; Stagg, Angela; Burkhoff, Daniel; Hasenfuß, Gerd.

In: JACC: Heart Failure, 01.01.2018.

Research output: Contribution to journalArticle

Abraham, WT, Kuck, KH, Goldsmith, RL, Lindenfeld, JA, Reddy, VY, Carson, PE, Mann, DL, Saville, B, Parise, H, Chan, R, Wiegn, P, Hastings, JL, Kaplan, AJ, Edelmann, F, Luthje, L, Kahwash, R, Tomassoni, GF, Gutterman, DD, Stagg, A, Burkhoff, D & Hasenfuß, G 2018, 'A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation', JACC: Heart Failure. https://doi.org/10.1016/j.jchf.2018.04.010
Abraham, William T. ; Kuck, Karl Heinz ; Goldsmith, Rochelle L. ; Lindenfeld, Jo Ann ; Reddy, Vivek Y. ; Carson, Peter E. ; Mann, Douglas L. ; Saville, Benjamin ; Parise, Helen ; Chan, Rodrigo ; Wiegn, Phi ; Hastings, Jeffrey L. ; Kaplan, Andrew J. ; Edelmann, Frank ; Luthje, Lars ; Kahwash, Rami ; Tomassoni, Gery F. ; Gutterman, David D. ; Stagg, Angela ; Burkhoff, Daniel ; Hasenfuß, Gerd. / A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. In: JACC: Heart Failure. 2018.
@article{a89982a7a5ca437e9d94c3b3cce63fe7,
title = "A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation",
abstract = "Objectives: The authors sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25{\%} and 45{\%}. Background: CCM therapy for New York Heart Association (NYHA) functional class III and IV heart failure (HF) patients consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. Methods: A total of 160 patients with NYHA functional class III or IV symptoms, QRS duration <130 ms, and ejection fraction ≥25{\%} and ≤45{\%} were randomized to continued medical therapy (control, n = 86) or CCM (treatment, n = 74, unblinded) for 24 weeks. Peak VO2 (primary endpoint), Minnesota Living With Heart Failure questionnaire, NYHA functional class, and 6-min hall walk were measured at baseline and at 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis with 30{\%} borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events with a pre-specified lower bound of 70{\%}. Results: The difference in peak VO2 between groups was 0.84 (95{\%} Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min, satisfying the primary endpoint. Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 0.001), and 6-min hall walk (p = 0.02) were all better in the treatment versus control group. There were 7 device-related events, yielding a lower bound of 80{\%} of patients free of events, satisfying the primary safety endpoint. The composite of cardiovascular death and HF hospitalizations was reduced from 10.8{\%} to 2.9{\%} (p = 0.048). Conclusions: CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations. (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure; NCT01381172)",
keywords = "exercise tolerance, heart failure, peak VO, QRS duration, quality of life",
author = "Abraham, {William T.} and Kuck, {Karl Heinz} and Goldsmith, {Rochelle L.} and Lindenfeld, {Jo Ann} and Reddy, {Vivek Y.} and Carson, {Peter E.} and Mann, {Douglas L.} and Benjamin Saville and Helen Parise and Rodrigo Chan and Phi Wiegn and Hastings, {Jeffrey L.} and Kaplan, {Andrew J.} and Frank Edelmann and Lars Luthje and Rami Kahwash and Tomassoni, {Gery F.} and Gutterman, {David D.} and Angela Stagg and Daniel Burkhoff and Gerd Hasenfu{\ss}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jchf.2018.04.010",
language = "English (US)",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation

AU - Abraham, William T.

AU - Kuck, Karl Heinz

AU - Goldsmith, Rochelle L.

AU - Lindenfeld, Jo Ann

AU - Reddy, Vivek Y.

AU - Carson, Peter E.

AU - Mann, Douglas L.

AU - Saville, Benjamin

AU - Parise, Helen

AU - Chan, Rodrigo

AU - Wiegn, Phi

AU - Hastings, Jeffrey L.

AU - Kaplan, Andrew J.

AU - Edelmann, Frank

AU - Luthje, Lars

AU - Kahwash, Rami

AU - Tomassoni, Gery F.

AU - Gutterman, David D.

AU - Stagg, Angela

AU - Burkhoff, Daniel

AU - Hasenfuß, Gerd

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objectives: The authors sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25% and 45%. Background: CCM therapy for New York Heart Association (NYHA) functional class III and IV heart failure (HF) patients consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. Methods: A total of 160 patients with NYHA functional class III or IV symptoms, QRS duration <130 ms, and ejection fraction ≥25% and ≤45% were randomized to continued medical therapy (control, n = 86) or CCM (treatment, n = 74, unblinded) for 24 weeks. Peak VO2 (primary endpoint), Minnesota Living With Heart Failure questionnaire, NYHA functional class, and 6-min hall walk were measured at baseline and at 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis with 30% borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events with a pre-specified lower bound of 70%. Results: The difference in peak VO2 between groups was 0.84 (95% Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min, satisfying the primary endpoint. Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 0.001), and 6-min hall walk (p = 0.02) were all better in the treatment versus control group. There were 7 device-related events, yielding a lower bound of 80% of patients free of events, satisfying the primary safety endpoint. The composite of cardiovascular death and HF hospitalizations was reduced from 10.8% to 2.9% (p = 0.048). Conclusions: CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations. (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure; NCT01381172)

AB - Objectives: The authors sought to confirm a subgroup analysis of the prior FIX-HF-5 (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure) study showing that cardiac contractility modulation (CCM) improved exercise tolerance (ET) and quality of life in patients with ejection fractions between 25% and 45%. Background: CCM therapy for New York Heart Association (NYHA) functional class III and IV heart failure (HF) patients consists of nonexcitatory electrical signals delivered to the heart during the absolute refractory period. Methods: A total of 160 patients with NYHA functional class III or IV symptoms, QRS duration <130 ms, and ejection fraction ≥25% and ≤45% were randomized to continued medical therapy (control, n = 86) or CCM (treatment, n = 74, unblinded) for 24 weeks. Peak VO2 (primary endpoint), Minnesota Living With Heart Failure questionnaire, NYHA functional class, and 6-min hall walk were measured at baseline and at 12 and 24 weeks. Bayesian repeated measures linear modeling was used for the primary endpoint analysis with 30% borrowing from the FIX-HF-5 subgroup. Safety was assessed by the percentage of patients free of device-related adverse events with a pre-specified lower bound of 70%. Results: The difference in peak VO2 between groups was 0.84 (95% Bayesian credible interval: 0.123 to 1.552) ml O2/kg/min, satisfying the primary endpoint. Minnesota Living With Heart Failure questionnaire (p < 0.001), NYHA functional class (p < 0.001), and 6-min hall walk (p = 0.02) were all better in the treatment versus control group. There were 7 device-related events, yielding a lower bound of 80% of patients free of events, satisfying the primary safety endpoint. The composite of cardiovascular death and HF hospitalizations was reduced from 10.8% to 2.9% (p = 0.048). Conclusions: CCM is safe, improves exercise tolerance and quality of life in the specified group of HF patients, and leads to fewer HF hospitalizations. (Evaluate Safety and Efficacy of the OPTIMIZER System in Subjects With Moderate-to-Severe Heart Failure; NCT01381172)

KW - exercise tolerance

KW - heart failure

KW - peak VO

KW - QRS duration

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=85046786522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046786522&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2018.04.010

DO - 10.1016/j.jchf.2018.04.010

M3 - Article

C2 - 29754812

AN - SCOPUS:85046786522

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

ER -